Abstract 3136
Background
The orally administered combination trifluridine and tipiracil hydrochloride (TAS-102) has been approved as third line treatment in metastatic colorectal cancer, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.
Methods
We performed an updated multicentre retrospective observational study of patients with metastatic colorectal cancer, receiving TAS-102 as third line treatment between 2016 and 2019 in 8 cancer centers across the UK. Medical records were reviewed for clinicopathological characteristics, treatment, survival and toxicity outcomes. Prognostic and predictive factors were identified with uni-and multivariate regression analyses.
Results
A total of 236 patients were included. Median age was 69 years (31-89). All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG > 2. Median duration of TAS-102 treatment was 3 months (0.2-25.9), with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 months (95%CI 6.5-8.6) and median PFS 3.3 months (95%CI 3.01-3.57). A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. Neutropenia was present in 53%, (>G3 34%) with 4.6% cases of neutropaenic fever. Thrombocytopenia was less frequent 11% (>G3 1.6%). Fatigue was reported in 67.3% (G3 9%), nausea 30% (G3 3.3%) and diarrhoea 24.5% (G3 2%). Baseline Neutrophil to Lymphocyte ratio (NLR) <5 and CEA <200 had favourable prognostic (HR: 0.52 and 0.39, p < 0.001) and predictive value (OR: 4.1 and 6.7, p < 0.05). Development of G3 neutropenia predicted treatment response (OR: 0.32, p < 0.001). Following TAS-102 treatment 41% were referred for Phase I trial or rechallenged with chemotherapy.
Conclusions
These results are consistent with the efficacy and toxicity outcomes from RECOURSE study. However, lower disease control rates and higher rates of dose reductions are seen in the real-world population. Pre-treatment NLR and CEA could serve as potential markers for patient selection. Prospective validation is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Stavraka: Travel / Accommodation / Expenses: Servier; Travel / Accommodation / Expenses: Amgen. V. Aggelis: Travel / Accommodation / Expenses: Amgen. T.J. Iveson: Advisory / Consultancy: Servier; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Bristol-Myers Squibb. K. Shiu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Guardant Health; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck KGaA; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sirtex; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Servier. M.E. Hill: Honoraria (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Travel / Accommodation / Expenses: Servier; Honoraria (self), Travel / Accommodation / Expenses: Merck; Honoraria (self), Travel / Accommodation / Expenses: Roche. P.J. Ross: Research grant / Funding (self): Sanofi; Honoraria (self), Travel / Accommodation / Expenses: Servier; Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self): Sirtex; Honoraria (self): Celgene; Honoraria (self): Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
2667 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC).
Presenter: Takeshi Kawakami
Session: Poster Display session 2
Resources:
Abstract
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract